Chelsea and Westminster Hospital
NHS Foundation Trust

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group

Summary of Main Points from the Meeting held on Monday 26th February 2024

2. Minutes and Summary Notes from last meeting

This meeting was held via Teams. The Minutes and Summary notes of the Medicines Group Meeting held on 11th December 2023 were approved. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda in due course.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

4.1 Formulary Applications

Full Applications

- **Iloprost 50micrograms/0.5ml Concentrate for Solution for Infusion**

Requested by: Rheumatology
Indication: Severe Raynaud's Disease
Proposal: Add to the formulary for prescribing in line with its licensed indication
Rational: Has been used in the Trust as an unlicensed formulation. This product was granted a license recently for Raynaud's Disease.
Cost: £72 per day - £360 for 5-day course - £2,880 per patient per annum
Likely to treat: 10 patients per year at CW Site and 8 patients pre year at WMUH Site.
Outcome: Approved for addition to the Trust Formulary

Ex-Panel

- **Triptorelin Pamoate 22.5mg (Sustained Release) Injection (Decapeptyl® SR)**

Requested by: Paediatrics
Indication: Treatment of central precocious puberty in children 2 years and older
Proposal: Add to the formulary for prescribing in line with its licensed indication
Rational: Currently the 3mg (SR - 4 weekly) and 11.25mg (SR - 12 weekly) 3.75mg (Depot - 4 weekly) preparations are currently included on the formulary. The addition of a longer acting 22.5mg (SR - 24 weekly) formulation will reduce the out-patient clinic attendance frequency for patients
Cost: NHS List price = £414 per injection
Note. The 11.25mg (12-weekly) injection routinely used, carries a cost price of £207, therefore, there is no additional cost associated with the use of the 22.5mg formulation in place of using 2 x 11.25mg SR injection.
Likely to treat: Estimate of 15 units per year
Outcome: Approved for addition to the Trust Formulary

- **Risankizumab (Skyrizi®)**
  - 150mg Pre-filled syringe
  - 360mg Solution for SC injection cartridge
  - 600mg Solution for infusion

Proposal: Add to the formulary for prescribing in line with its licensed indication and NICE TA888. To remove 75mg pre-filled syringe which has been discontinued commercially.
Rational for adding to the formulary:
NICE TA888 - Risankizumab for previously treated moderately to severely active Crohn's Disease. CWFT is commissioned for adolescents 16-17 for moderate to severe Crohn's Disease who have had previous treatment failures (e.g. Anaphylactic reactions to some of the first line options or inadequate disease management).
In adolescents with severe Crohn's Disease, Risankizumab may be an option instead of surgery to remove part of the bowel.

Dosing is in the BNFc: 600mg infusion x3 followed by 360mg SC 8-weekly dosing (Administered at CWFT in PACC)

Select a form from the ones below:

Commissioner	Form Description	
CCG	2020/21 Risankizumab for Severe Plaque Psoriasis [v1] [see SWL Drug pathway - Psoriasis; Sept 2019]	Select form
CCG	Risankizumab for moderately to severely active Crohn's disease (SWL*)	Select form
CCG	Risankizumab for Psoriatic Arthritis - NICE TA803 - Initiation (SWL*)	Select form
NHSE	[RISA01]_ ver1.0 Early Access to Medicines Scheme Application Form - Risankizumab for the treatment of adolescent patients aged 16 to 17 years old with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant or contraindicated to TNFa antagonist therapies	Select form
NHSE	M4C NHS England V1.1 - Initial Funding Application - Risankizumab for previously treated moderately to severely active Crohn's disease (in relation to NICE TA888)	Select form
NHSE	NHS England - Initial Funding Application - Risankizumab for previously treated moderately to severely active Crohn's disease (NICE TA888)	Select form

For Individual Funding Requests please follow this link to the web-based portal

Cost: All preparations (Regardless of strength) are £1,815 ex VAT per unit.
Likely to treat: Estimated at 5 patients per year
Outcome: Approved for addition to the Trust Formulary

- **Nicotine Patch 25mg/16 hours Patch**

Requested by: Medicine (Smoking Cessation Team)
Indication: Management of Nicotine dependant symptoms
Proposal: Add to the formulary for prescribing in line with the Trust smoking cessation project in line with its licensed indication
Rational: This is indicated for patients who smoke >15 cigarettes a day and do not smoke within 30minutes of waking. Currently do not have a patch included on our formulary that is licensed for this indication.
Cost: The price of 7-patch pack of the 25mg/16hour patches is £9.60 which is similar to the price of the other patches included on the formulary (7x 21mg/24hour patches = £9.64 & 7x 15mg/16hour patches = £12)
Likely to treat: 1,500 per year
Other information: This strength of patches are on the NWL Formulary.
Outcome: Approved for addition to the Trust Formulary

- **Prednisolone 25mg Tablets**

Historically not included on the Trust formulary due to a significant cost difference in comparison with 5mg Tablets. Significant difference is no longer present:

- 25mg Tablets: 25p
- 5mg Tablets: 9p

Proposal: Add to the formulary to reduce pill burden as there is no longer a significant difference in cost.
Outcome: Approved for addition to the Trust Formulary

Removals

- **Risankizumab (Skyrizi®) 75mg pre-filled syringe**

Proposal:Rremove from the formulary on account of this preparation being discontinued by manufacturers.
Outcome: Approved for removal from the Trust Formulary

NICE Approved drug applications

- **TA922 - Daridorexant for treating long-term insomnia (18/10/2023)**

Proposal: Add to the formulary in line with NICE TA922
Approved by Chair's Action on 5/01/2024

Outcome: Approved for addition to the Trust Formulary

- **TA925 - Mirikizumab for treating moderately to severely active ulcerative colitis (25/10/2023)**

Proposal: Add to the formulary in line with NICE TA925
Approved by Chair's Action on 5/01/2024
Outcome: Approved for addition to the Trust Formulary

- **TA927 - Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (17/10/2023)**

Proposal: Add to the formulary in line with NICE TA927
Approved by Chair's Action on 5/01/2024
Outcome: Approved for addition to the Trust Formulary

Pharmacoeconomic Board requests

- **Nil**

4.2 Trust Medicines Policy

- **TMP: Section 1 - Introduction**

Routine review and update
- Expansion of the section relating to the Trust Medicines Optimisation Report
- Update to Appendix 1.2
- Removal of the Trust Homecare Group

Outcome: Approved

- **TMP: Section 2 - Prescribing of medicines (Jan update)**

Updated in line with the National Patient Safety Alert (Valproate: organisations to prepare for new regulatory measures for oversight of prescribing to new patients and existing female patients (NatPSA/2023/013/MHRA).
- New section added relating to valpoate

Note: This was approved by Chair's action on 26th January on account of the 31/01/24 deadline.
Outcome: Approved

- **TMP: Section 3 - Ordering and supplying of medicines**

Updated in line with the National Patient Safety Alert (Valproate: organisations to prepare for new regulatory measures for oversight of prescribing to new patients and existing female patients (NatPSA/2023/013/MHRA).
- New section added relating to valpoate

Note: This was approved by Chair's action on 26th January on account of the 31/01/24 deadline.
Outcome: Approved

- **TMP: Section 8 - Administration of medicines**

Updated to include insulin as a medicine that requires double-checking on administration in line with recommendation put forward by SI Investigation Panel.
Note: This was approved by Chair's action on 29th January to permit early circulation of the Medicines Bulletin to promote learning and awareness of the incident.
Outcome: Approved

- **TMP: Section 30 - Supply of Over-labelled/Pre-packed medicines from Wards/Departments/Out-patient clinics**

Addition of the following as a clinical areas at CWH that can operate in line with this policy to support patient discharge:
- Labour Ward
- Josephine Barnes Ward
- Birthing Centre

Outcome: Approved

- **TMP: Section 2 - Prescribing of medicines (Feb update)**

Updated in line with Pharmacist Checklist - Guidance for Dispensing Oral Isotretinoin (MHRA, October 2023)

Outcome: Approved

- **TMP: Section 2 - Prescribing of medicines (Mar update)**

Updated to include a new section relating to out-prescription charge exemptions.
Outcome: Approved

- **TMP: Section 6 - Controlled Drugs**

Removal of the need to have 2 signatures on electronic requests for stock controlled drugs
Outcome: Approved

4.3 Medicines Optimisation

- **Trust Covid-19 Vaccine Handling and Management Policy**

Trust cross-site policy that details the processes involved in the handling and management of Covid-19 vaccines
Existing policy that has been updated following a routine review
Updates include:

- Update to list of relevant Covid-19 vaccine SOPs
- Updated for the brand of Covid-19 vaccines currently procured and administered within the Trust
- Updated for the types of documentation that support the administration of Covid-19 vaccines within the Trust

Outcome: Approved

- **Guideline for the management of adults with diabetes undergoing elective and emergency surgery and procedures**

Newly drafted Trust cross-site guideline for the perioperative management of Diabetic patients.

This guidelines been drafted with input from the following key stakeholders:

- Planned Care
- Pharmacy
- Diabetes & Endocrinology

This guideline been approved at:

- Clinical Governance meeting - Diabetes & Endocrinology

Outcome: Approved

4.4 NICE Technical Appraisals and Guidance

a) NICE Technology Appraisals published

19 TA appraisals published since previous TMG meeting 2024

TA933 Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) (29/11/2023)
Formulary status / Action
Nil - Terminated Appraisal

TA934 Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms (29/11/2023)
Formulary status / Action
Not included on the formulary
Action: Nil - Not applicable as condition not treated at CWFT

TA935 Secukinumab for treating moderate to severe hidradenitis suppurativa (06/12/2023)
Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 20 patients per year
Numbers likely to treat at WMUH site: 20 patients per year

TA936 - Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) (30/11/2023)
Formulary status / Action
Nil - Terminated Appraisal

TA937 - Targeted-release budesonide for treating primary IgA nephropathy (20/12/2023)
Formulary status / Action
Not included on the formulary
Action: Nil - Not applicable as condition not treated at CWFT

TA938 - Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (Terminated appraisal) (07/12/2023)
Formulary status / Action
Nil - Terminated Appraisal

TA939 - Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (13/12/2023)
Formulary status / Action
Included on the formulary for another indication
Action: Nil - Not applicable as condition not treated at CWFT

TA940 - Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) (20/12/2023)
Formulary status / Action
Nil - Terminated Appraisal

TA941 - Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) (20/12/2023)
Formulary status / Action
Nil - Terminated Appraisal

TA942 - Empagliflozin for treating chronic kidney disease (20/12/2023)
Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 50 patients per year
Numbers likely to treat at WMUH site: 50 patients per year

TA943 - Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (19/12/2023)
Formulary status / Action
Nil - Medical device

TA944 - Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (10/01/2024)
Formulary status / Action
Included on the formulary for another indication
Action: Nil - Not applicable as condition not treated at CWFT

TA945 - Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) (30/01/2024)
Formulary status / Action
Nil - Terminated Appraisal

TA946 - Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (17/01/2024)
Formulary status / Action
Included on the formulary for another indication
Action: Nil - Not applicable as condition not treated at CWFT
TA947 - Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments (31/01/2024)

Formulary status / Action
Not included on the formulary
Action: Nil - Not applicable as condition not treated at CWFT

TA948 - Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (31/01/2024)
Formulary status / Action
Not included on the formulary
Action: Nil - Not applicable as condition not treated at CWFT

TA949 - Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (07/02/2024)
Formulary status / Action
Not included on the formulary
Action: Nil - Not applicable as condition not treated at CWFT

TA950 - Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (07/02/2024)
Formulary status / Action
Add to the formulary following receipt of an application form from the Oncology Department

TA951 - Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (07/02/2024)
Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 2 patients per year
Numbers likely to treat at WMUH site: 0 patient per year

b) NICE Highly Specialised Technology Appraisals published since last meeting

2 HST appraisal published since previous TMG meeting

HST29 - Velmanase alfa for treating alpha-mannosidosis (13/12/2023)
Formulary status / Action
Nil - Not applicable to CWFT

HST30 - Sebelipase alfa for treating Wolman disease (10/01/2024)
Formulary status / Action
Nil - Not applicable to CWFT

4.5 Items for noting

- **Trust Non-Medical Prescribing Register - December 2023**

Trust Non-Medical Prescribing Register for December 2023
Outcome: Noted

- **Medication Safety Bulletin: Hyperkalaemia in Adult Patients**

Medication Safety Bulletin relating to Hyperkalaemia in Adult Patients
Outcome: Noted

- **Medication Safety Bulletin: Summary of medication related incidents - 2023**

Medication Safety Bulletin relating to medication related incidents - 2023
Outcome: Noted

- **MHRA Drug Safety Update - December 2023**

MHRA update for December 2023
Outcome: Noted

- **MHRA Drug Safety Update - January 2024**

MHRA update for January 2024
Outcome: Noted

- **MHRA Drug Safety Update - February 2024**

MHRA update for February 2024
Outcome: Noted

4.6 Meeting minutes for noting

- **Nil**

5. Any other business

- **Nil**

6. Date of next meeting

Next meeting
Date 29th April 2024
Time: 8am-9am
Location: via Teams